Trade Daré Bioscience, Inc. - DARE CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0464 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023346% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001124% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 3.3218 |
| Open | 3.3218 |
| 1-Year Change | 926.2% |
| Day's Range | 3.3218 - 3.3318 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Jan 16, 2025 | 3.3218 | 0.0000 | 0.00% | 3.3218 | 3.3318 | 3.3118 |
| Jan 15, 2025 | 3.3218 | 0.0000 | 0.00% | 3.3218 | 3.3218 | 3.1918 |
| Jan 14, 2025 | 3.3218 | 0.0000 | 0.00% | 3.3218 | 3.3418 | 3.2718 |
| Jan 13, 2025 | 3.3118 | 0.2400 | 7.81% | 3.0718 | 3.3618 | 3.0718 |
| Jan 10, 2025 | 3.0718 | -0.1700 | -5.24% | 3.2418 | 3.2418 | 3.0518 |
| Jan 8, 2025 | 3.1818 | -0.1300 | -3.93% | 3.3118 | 3.3518 | 3.1718 |
| Jan 7, 2025 | 3.3518 | 0.0600 | 1.82% | 3.2918 | 3.3618 | 3.2918 |
| Jan 6, 2025 | 3.3218 | -0.0400 | -1.19% | 3.3618 | 3.3618 | 3.2918 |
| Jan 3, 2025 | 3.3218 | 0.1300 | 4.07% | 3.1918 | 3.3618 | 3.1918 |
| Jan 2, 2025 | 3.2118 | 0.1100 | 3.55% | 3.1018 | 3.2518 | 3.1018 |
| Dec 31, 2024 | 3.0718 | -0.0300 | -0.97% | 3.1018 | 3.2018 | 2.9518 |
| Dec 30, 2024 | 3.2018 | 0.0700 | 2.24% | 3.1318 | 3.2718 | 3.1118 |
| Dec 27, 2024 | 3.2518 | 0.0100 | 0.31% | 3.2418 | 3.2718 | 3.1818 |
| Dec 26, 2024 | 3.2918 | 0.1200 | 3.78% | 3.1718 | 3.3118 | 3.1718 |
| Dec 24, 2024 | 3.1718 | 0.0000 | 0.00% | 3.1718 | 3.2018 | 3.0718 |
| Dec 23, 2024 | 3.1618 | -0.0100 | -0.32% | 3.1718 | 3.2218 | 3.1618 |
| Dec 20, 2024 | 2.6918 | -0.2000 | -6.92% | 2.8918 | 2.9018 | 2.6718 |
| Dec 19, 2024 | 3.0218 | -0.1200 | -3.82% | 3.1418 | 3.1418 | 2.8918 |
| Dec 18, 2024 | 3.1718 | -0.0100 | -0.31% | 3.1818 | 3.1818 | 3.1618 |
| Dec 17, 2024 | 3.1718 | 0.0000 | 0.00% | 3.1718 | 3.1818 | 3.1618 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Daré Bioscience, Inc. Company profile
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing products for women''s health in the United States. The company develops therapies in the areas of contraception, fertility, and sexual and vaginal health. Its products in advanced clinical development include DARE-BV1, a bioadhesive hydrogel formulated with clindamycin phosphate 2% to treat bacterial vaginosis in a single administration that has completed Phase 3 clinical trials; Ovaprene, a hormone-free monthly vaginal contraceptive; and Sildenafil Cream, a cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder. The company''s Phase 1-ready products are DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for the treatment of vasomotor symptoms in hormone therapy; DARE-VVA1, a vaginally delivered formulation of tamoxifen to treat vulvar vaginal atrophy in patients with hormone-receptor positive breast cancer; and DARE-FRT1, an intravaginal ring containing bio-identical progesterone for the prevention of preterm birth and broader luteal phase support as part of an in vitro fertilization treatment plan. Its products in pre-clinical stage include DARE-LARC1, a combination product designed to provide reversible contraception; ORB-204 and ORB-214, an injectable formulations of etonogestrel to provide contraception over 6-month and 12-month periods; and DARE-RH1, a non-hormonal contraception for men and women. The company is headquartered in San Diego, California.| Industry: | Biotechnology & Medical Research (NEC) |
3655 Nobel Dr Ste 260
SAN DIEGO
CALIFORNIA 92122-1050
US
News
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025
Euro forecast: third party data roundup
In 2024, the euro’s outlook appeared more stable. Read on for our 2025 and beyond insights.
12:40, 31 December 2024
Pi Network coin price prediction: Third party price target
Discover the Pi Network coin price predictions for 2025 onward, with analyst outlooks, price targets and CFDs trading strategies on Capital.com
13:51, 13 December 2024
Projected US interest rates in 5 years: Third party round up
As the US central bank starts its cutting cycle, what are the projected interest rates in 5 years?
14:28, 12 December 2024
Projected UK interest rates in 5 years
Bank of England (BoE) cut rates for the first time in August 2024, with further easing expected in the coming months. But how low are rates likely to go?
11:20, 12 December 2024
Dogecoin (DOGE) price prediction 2025-2030: Could Dogecoin reach $1? - Third party price target
We look at the meme coin’s price performance and the latest DOGE price predictions
08:37, 12 December 2024
Gold price predictions for the next five years: Third party data round up
Explore the future of gold prices and whether the yellow metal will continue its upward trend in the coming years.
09:13, 6 December 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com